{
  "meta": {
    "title": "Recentupdates_Test",
    "url": "https://brainandscalpel.vercel.app/recentupdates-test-e76b2aa7.html",
    "scrapedAt": "2025-11-30T12:45:13.642Z"
  },
  "questions": [
    {
      "text": "You are at a health camp screening children in a community for malnutrition. According to the new WHO growth standards, the cut-off value of mid-upper arm circumference to define severe acute malnutrition is _______.",
      "choices": [
        {
          "id": 1,
          "text": "11 cm"
        },
        {
          "id": 2,
          "text": "11.5 cm"
        },
        {
          "id": 3,
          "text": "12 cm"
        },
        {
          "id": 4,
          "text": "12.5 cm"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The cut-off value of mid-upper arm circumference to define severe acute malnutrition is <strong>11.5 cm</strong> according to the new WHO growth standards.</p>\n<p>Mid-upper arm circumference:</p>\n<ul>\n<li>Used in children between 6 to 60 months.</li>\n<li>Measured between the acromion and olecranon process.</li>\n<li>It is an age-independent parameter (between 6-60 months).</li>\n</ul>\n<p>MUAC tape cut-offs:</p>\n<table>\n<tbody>\n<tr>\n<td>Color</td>\n<td>Measurements</td>\n<td>Indication</td>\n</tr>\n<tr>\n<td>Red</td>\n<td>&lt;11.5 cm</td>\n<td>Severe acute malnutrition</td>\n</tr>\n<tr>\n<td>Yellow</td>\n<td>11.5 to 12.5 cm</td>\n<td>Under-nourished</td>\n</tr>\n<tr>\n<td>Green</td>\n<td>&gt;12.5 cm</td>\n<td>Normal</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: World Health Organization (WHO) classification of nutritional status of infants and children</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Nutritional status</strong></span></div>\n</td>\n<td>\n<div><span><strong>Criteria </strong>(from birth to 5 years)</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<p><span>Obese</span></p>\n</td>\n<td>\n<p><span><strong>Weight-for-height</strong>/length&nbsp;&gt;3 SD</span></p>\n<p><span><strong>BMI-for-</strong>age &gt;3 SD</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Overweight</span></td>\n<td>\n<p><span><strong>Weight-for-height</strong>/length&nbsp;&gt;2 SD and &le;3 SD</span></p>\n<p><span><strong>BMI-for-age</strong> &gt;2 SD and &le;3 SD</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Moderately underweight</span></td>\n<td><span><strong>Weight-for-age</strong> &lt;&ndash;2 SD and &ge;&ndash;3 SD</span></td>\n</tr>\n<tr>\n<td><span>Severely underweight</span></td>\n<td><span><strong>Weight-for-age</strong> &lt;&ndash;3 SD</span></td>\n</tr>\n<tr>\n<td><span>Moderate acute malnutrition</span></td>\n<td>\n<p><span><strong>Weight-for-height</strong>/length&nbsp;&le;&ndash;2 SD and &ge;&ndash;3 SD</span></p>\n<p><span><strong>BMI-for-age</strong> &le;&ndash;2 SD and &ge;&ndash;3 SD</span></p>\n<p><span><strong>Mid-upper arm circumference</strong> &ge;115&nbsp;mm and &lt;125&nbsp;mm</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Severe acute malnutrition</span></td>\n<td>\n<p><span><strong>Weight-for-height</strong>/length&nbsp;&lt;&ndash; 3 SD</span></p>\n<p><span><strong>BMI-for-age</strong> &lt;&ndash; 3 SD</span></p>\n<p><span><strong>Mid-upper arm circumference</strong> &lt;115 mm</span></p>\n<p><span>Bilateral pitting edema</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Moderately stunted (or) moderate chronic malnutrition</span></td>\n<td><span><strong>Height/Length-for-age</strong> &le;&ndash;2 SD and &ge;&ndash;3 SD</span></td>\n</tr>\n<tr>\n<td><span>Severely stunted (or) severe chronic malnutrition</span></td>\n<td><span><strong>Height/Length-for-age</strong> &lt;&ndash;3 SD</span></td>\n</tr>\n<tr>\n<td><span>Moderately wasted</span></td>\n<td><span><strong>Weight-for-height</strong>/length &le;&ndash;2 SD and &ge;&ndash;3 SD</span></td>\n</tr>\n<tr>\n<td><span>Severely wasted</span></td>\n<td><span><strong>Weight-for-height</strong>/length &lt;-3 SD</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>SD</strong> - Standard deviation (from the median)</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9648",
      "difficulty": "easy"
    },
    {
      "text": "Under Rajiv gandhi shramik kalyan yojana, an insured person is entitled to claim unemployment allowance of 50% of wage for a maximum period of:",
      "choices": [
        {
          "id": 1,
          "text": "2 years"
        },
        {
          "id": 2,
          "text": "6 months"
        },
        {
          "id": 3,
          "text": "1 year"
        },
        {
          "id": 4,
          "text": "3 years"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>An insured person is entitled to claim unemployment allowance of 50% of wage for a maximum period of <strong>2 years</strong> under rajiv gandhi shramik yojana.</p>\n<p>Earlier, an insured person was entitled to claim unemployment allowance for a maximum period of <strong>6 months.</strong></p>\n<p><strong>Rajiv gandhi shramik kalyan yojana</strong> is an ESI scheme of unemployment allowance that came into effect from 1st April, 2005.</p>\n<p>As per this scheme, an insured person who becomes unemployed after being insured three or more years, due to closure of factory/establishment, retrenchment or permanent invalidity are entitled to:</p>\n<ul>\n<li>Unemployment allowance equal to <strong>50% of wage for a maximum period of upto 2 years.</strong></li>\n<li><strong>Medical care for self and family</strong> from ESI hospitals/dispensaries during the period of unemployment allowance.</li>\n<li><strong>Vocational training provided for upgrading skills</strong> - expenditure on fee/travelling allowance borne by ESIC.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9649",
      "difficulty": "medium"
    },
    {
      "text": "Injectable contraceptive DMPA is introduced under which of the following programme?",
      "choices": [
        {
          "id": 1,
          "text": "Antara"
        },
        {
          "id": 2,
          "text": "Chhaya"
        },
        {
          "id": 3,
          "text": "Saheli"
        },
        {
          "id": 4,
          "text": "Novex"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Injectable contraceptive DMPA is introduced under <strong>Antara programme.</strong></p>\n<p>The dosage is <strong>150 mg i.m every 3 months.</strong></p>\n<p>Mechanism of action:</p>\n<ul>\n<li>Inhibition of ovulation</li>\n<li>Cervical mucus thickening and thereby preventing sperm penetration</li>\n<li>Endometrial atrophy preventing implantation.</li>\n</ul>\n<p>Chhaya, Saheli and Novex are once a week non-steroidal oral pills.</p><hr><h3>Related Pearl: Hormonal contraceptives</h3><div dir=\"ltr\">\n<p><strong>Oral pills:</strong></p>\n<ul>\n<li>Combined oral contraceptive pills (COC)\n<ul>\n<li>Mala D -&nbsp;Levonorgestrel 0.15 mg + Ethinyl estradiol &nbsp;0.03 mg + Ferrous fumarate</li>\n<li>Mala N -&nbsp;Levonorgestrel 0.15 mg +&nbsp;Ethinyl estradiol &nbsp;0.03 mg + Ferrous fumarate&nbsp;(Govt. supply, free of cost)</li>\n</ul>\n</li>\n<li>Progesterone only pills (POP) - suitable for lactating women\n<ul>\n<li>Norethisterone 350 &mu;g</li>\n<li>Norgestrel 75 &mu;g</li>\n<li>Levonorgestrel (LNG) 30 &mu;g</li>\n</ul>\n</li>\n<li>Once a month or long-acting pills - highly disappointing results\n<ul>\n<li>Quinestrol (long-acting estrogen) + short-acting progesterone</li>\n</ul>\n</li>\n<li>Gossypol - male pill : Cottonseed derivative and causes azoospermia and severe oligospermia</li>\n<li>Post-coital pills or interceptive\n<ul>\n<li>Levonorgestrel 0.75 mg, 2 doses, 12 hours apart</li>\n<li>Mifepristone 10-600 mg</li>\n<li>Ulipristal 30 mg, within 5 days of intercourse</li>\n<li>Centchroman 60 mg, 2 tablets, within 24 hrs of intercourse</li>\n<li>GnRH agonists &nbsp;</li>\n<li>CuT IUCD, inserted within 5 days</li>\n</ul>\n</li>\n</ul>\n<p><strong> Injectable contraceptives</strong></p>\n<ul>\n<li>Progesterone only injectables\n<ul>\n<li>DMPA&nbsp;150 mg IM every 3 months</li>\n<li>NET-EN&nbsp;200 mg IM every 2 months</li>\n</ul>\n</li>\n<li>Combined injectables\n<ul>\n<li>Cyclofem - DMPA 25 mg + Estradiol cypionate 5 mg</li>\n<li>Mesigyna - NET-EN 50 mg &nbsp;+ Estradiol valerate 5 mg</li>\n</ul>\n</li>\n</ul>\n<p><strong> Subdermal implants</strong></p>\n<ul>\n<li>Norplant I -&nbsp;Levonorgestrel 35 mg</li>\n<li>Norplant II or Jadelle -&nbsp;2 rods with levonorgestrel 70 mg in each and released at a rate of 50 &mu;g/day &nbsp;</li>\n</ul>\n<p><strong>Others</strong></p>\n<ul>\n<li>Hormonal IUCD -&nbsp;Mirena which contains LNG 52 mg with release rate of&nbsp;20 &mu;g/day</li>\n<li>Orthoevra patch -&nbsp;Norelgestomin + Ethinyl estradiol weekly for 3 weeks, then patch free for 1 week</li>\n<li>Vaginal ring or Nuvaring - Etonogestrel + ethinyl estradiol daily release, use for 3 weeks with withdrawal for 1 week</li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9650",
      "difficulty": "easy"
    },
    {
      "text": "A 6-month old baby is presented to the opd with difficulty in sucking and swallowing. On examination, he has tongue fasciculations, frog leg posture and hypotonia. Which of the following can be used for the treatment of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Selinexor"
        },
        {
          "id": 2,
          "text": "Alpelisib"
        },
        {
          "id": 3,
          "text": "Erdafitinib"
        },
        {
          "id": 4,
          "text": "Onasemnogene abeparvovec"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of <strong>spinal muscular atrophy.</strong> <strong>Onasemnogene abeparvovec</strong> can be used for the treatment of this condition.</p>\n<p><strong>Onasemnogene abeparvovec </strong>is a <strong>recently approved gene therapy</strong> for the treatment of <strong>children less than 2 years of age with spinal muscular atrophy.</strong></p>\n<p>It is a recombinant adeno-associated viral vector containing complementary DNA encoding the normal human survival motor neuron protein (SMN1). It is for <strong>single-dose intravenous infusion only.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9651",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the semi-synthetic pleuromutilin antibiotic used for the treatment of community-acquired pneumonia in adults?",
      "choices": [
        {
          "id": 1,
          "text": "Levofloxacin"
        },
        {
          "id": 2,
          "text": "Lefamulin"
        },
        {
          "id": 3,
          "text": "Ceftaroline"
        },
        {
          "id": 4,
          "text": "Linezolid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Lefamulin</strong> is the first-in-class semi-synthetic pleuromutilin antibiotic used for the treatment of community-acquired pneumonia in adults.</p>\n<p>It has been recently approved by FDA.</p>\n<p><strong>Mechanism of action:</strong></p>\n<p>It inhibits bacterial protein synthesis by binding to the A and P sites of the peptidyl transferase center. The binding pocket of the bacterial ribosome closes around the mutilins core for an induced fit that prevents correct positioning of tRNA.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9652",
      "difficulty": "medium"
    },
    {
      "text": "The recently approved drug for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy is:",
      "choices": [
        {
          "id": 1,
          "text": "Risankizumab"
        },
        {
          "id": 2,
          "text": "Bremelanotide"
        },
        {
          "id": 3,
          "text": "Romosozumab"
        },
        {
          "id": 4,
          "text": "Caplacizumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Risankizumab</strong> is the recently approved drug for the treatment of moderate to severe plaque psoriasis in adults.</p>\n<p>It is an <strong>interleukin-23 antagonist.</strong></p>\n<p>The recommended dose is <strong>150 mg s.c at week 0, 4 and every 12 weeks thereafter.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9653",
      "difficulty": "medium"
    },
    {
      "text": "According to the new ACOG guidelines, the universal rectovaginal culture screening of pregnant women for group B streptococcus is recommended at:",
      "choices": [
        {
          "id": 1,
          "text": "35 to 37 weeks"
        },
        {
          "id": 2,
          "text": "36 0/7 to 37 6/7 weeks"
        },
        {
          "id": 3,
          "text": "38 to 39 weeks"
        },
        {
          "id": 4,
          "text": "34 6/7 to 35 6/7 weeks"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The universal rectovaginal culture screening for group B streptococcus is recommended at <strong>36 0/7 to 37 6/7 weeks</strong> according to the new ACOG guidelines.</p>\n<p>Previously, it was recommended at 35 to 37 weeks.</p>\n<p>Exceptions:</p>\n<ul>\n<li>Women with GBS bacteriuria during the current pregnancy</li>\n<li>Women who had an infant with invasive early-onset GBS infection in a previous pregnancy</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9654",
      "difficulty": "medium"
    },
    {
      "text": "The mechanism of action of pitolisant is:",
      "choices": [
        {
          "id": 1,
          "text": "H3 receptor inverse agonism"
        },
        {
          "id": 2,
          "text": "H1 receptor inverse agonism"
        },
        {
          "id": 3,
          "text": "H3 receptor agonism"
        },
        {
          "id": 4,
          "text": "H1 receptor agonism"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Pitolisant is an <strong>H3 receptor inverse agonist.</strong></p>\n<p>It has been recently approved by the FDA for the treatment of <strong>excessive daytime sleepiness in adults with narcolepsy.</strong></p>\n<p>Contraindications:</p>\n<ul>\n<li>End-stage renal disease</li>\n<li>Severe hepatic impairment</li>\n</ul>\n<p>Other drugs used for the treatment of daytime sleepiness are:</p>\n<ul>\n<li>Modafinil</li>\n<li>Solriamfetol</li>\n<li>Methylphenidate</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9655",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements are true among the given statements about TRALI?<br><br>A.\tTRALI type I occurs in patients with no concomitant risk factors for ARDS\nB.\tTRALI type II occurs in patients who have concomitant risk factors for ARDS\nC.\tThe presence of mild pre-transfusion ARDS excludes the diagnosis of TRALI",
      "choices": [
        {
          "id": 1,
          "text": "Only A"
        },
        {
          "id": 2,
          "text": "A and C"
        },
        {
          "id": 3,
          "text": "A and B"
        },
        {
          "id": 4,
          "text": "None of the given statements"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Statements A and B are true.</p>\n<p><strong>New consensus TRALI definition (2019):</strong></p>\n<ul>\n<li><strong>TRALI type I</strong> - patients who have no risk factors for ARDS and meet the following criteria:</li>\n</ul>\n<ol>\n<li>Acute onset</li>\n<li>Hypoxemia</li>\n<li>Clear evidence of bilateral pulmonary edema on imaging</li>\n<li>No evidence of left atrial hypertension or, if LAH is present, it is judged to not be the main contributor to the hypoxemia</li>\n<li>Onset during or within 6 hour of transfusion</li>\n<li>No temporal relationship to an alternative risk factor for ARDS</li>\n</ol>\n<ul>\n<li><strong>TRALI type II </strong>- patients who have risk factors for ARDS or who have existing mild ARDS and is judged to be due to transfusion based on:</li>\n</ul>\n<ol>\n<li>Findings as described in categories 1 to 5 of TRALI type I, and</li>\n<li>Stable respiratory status in the 12 hour before transfusion</li>\n</ol>\n<p><strong>NOTE:</strong> The term ‘Possible TRALI’ has been removed in the redefinition of TRALI.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9656",
      "difficulty": "medium"
    },
    {
      "text": "The second line of treatment for advanced hepatocellular carcinoma in patients with an AFP level >400 ng/ml and have been previously treated with sorafenib is?",
      "choices": [
        {
          "id": 1,
          "text": "Ramucirumab"
        },
        {
          "id": 2,
          "text": "Upadacitimib"
        },
        {
          "id": 3,
          "text": "Tenapanor"
        },
        {
          "id": 4,
          "text": "All of the above"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ramucirumab</strong> is the second line drug for the treatment of advanced hepatocellular carcinoma with an AFP&gt;400 ng/ml.</p>\n<p>Ramucirumab is a <strong>recombinant monoclonal antibody.</strong></p>\n<p>Mechanism of action: It inhibits vascular endothelial growth factor receptor 2 resulting in reduced tumor vascularity and growth.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9657",
      "difficulty": "hard"
    },
    {
      "text": "According to the 2019 ASCO guidelines, the optimal duration of adjuvant oxaliplatin chemotherapy for patients with completely resected stage III colon cancer who are at higher risk of recurrence (T4 and/or N2) is:",
      "choices": [
        {
          "id": 1,
          "text": "9 months"
        },
        {
          "id": 2,
          "text": "4 months"
        },
        {
          "id": 3,
          "text": "6 months"
        },
        {
          "id": 4,
          "text": "8 months"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The optimal duration of adjuvant oxaliplatin chemotherapy for patients with completely resected stage III colon cancer who are at higher risk of recurrence (T4 and/or N2) is <strong>6 months</strong> according to the latest ASCO guidelines.</p>\n<p>For patients at a <strong>low risk of recurrence</strong> (T1, T2 or T3 and/or N1), <strong>either 6 or 3 months</strong> of adjuvant chemotherapy is offered.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9658",
      "difficulty": "medium"
    },
    {
      "text": "Erythropoiesis stimulating agents are recommended for:",
      "choices": [
        {
          "id": 1,
          "text": "All non-chemotherapy associated anemias"
        },
        {
          "id": 2,
          "text": "Chemotherapy associated anemia whose cancer treatment is curative in intent"
        },
        {
          "id": 3,
          "text": "Low risk myelodysplastic syndromes and a serum erythropoietin level of <500IU/ml"
        },
        {
          "id": 4,
          "text": "All of the above"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Erythropoiesis stimulating agents are recommended for <strong>low risk myelodysplastic syndromes and a serum erythropoietin level of &lt;500IU/ml.</strong></p>\n<p>ESAs are recommended for:</p>\n<ul>\n<li>Chemotherapy associated anemia whose cancer treatment is not curative in intent and Hb&lt;10g/dL.</li>\n<li>Low risk myelodysplastic syndromes and a serum erythropoietin level of &lt;500IU/ml</li>\n</ul>\n<p>ESAs are NOT recommended for:</p>\n<ul>\n<li>Most of the patients with non-chemotherapy associated anemia</li>\n<li>Chemotherapy associated anemia whose cancer treatment is curative in intent because of increased risk of cancer progression or recurrence and thromboembolic events.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9659",
      "difficulty": "hard"
    },
    {
      "text": "Match the following:",
      "choices": [
        {
          "id": 1,
          "text": "A-iii, B-i, C-ii"
        },
        {
          "id": 2,
          "text": "A-iii, B-ii, C-i"
        },
        {
          "id": 3,
          "text": "A-ii, B-iii, C-i"
        },
        {
          "id": 4,
          "text": "A-i, B-ii, C-iii"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Siponimod</strong> is a sphingosine 1-phosphate receptor modulator. It has been recently approved by FDA for the treatment of <strong>active secondary progressive multiple sclerosis.</strong></p>\n<p><strong>Tenapanor</strong> is a sodium/hydrogen exchanger 3 inhibitor. It has been recently approved by FDA for the treatment of <strong>Irritable bowel syndrome with constipation.</strong></p>\n<p><strong>Afamelanotide</strong> is a synthetic analogue of alpha-melanocyte stimulating hormone. It increases sunlight tolerance. It has been recently approved by FDA for the treatment of <strong>erythropoietic protoporphyria.</strong></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/225639f5862c43bb9a0d2e08fb6533f6.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9660",
      "difficulty": "medium"
    },
    {
      "text": "The objective of LaQshya is:",
      "choices": [
        {
          "id": 1,
          "text": "To promote breastfeeding"
        },
        {
          "id": 2,
          "text": "To improve quality of care in labour room and maternity operation theatres"
        },
        {
          "id": 3,
          "text": "To promote use of contraception"
        },
        {
          "id": 4,
          "text": "Safe vaccination and universal vaccine coverage"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The objective of LaQshya is <strong>to improve quality of care in labour room and maternity operation theatres.</strong></p>\n<p>Government of India has launched <strong>LaQshya (Labour room Quality improvement Initiative)</strong> to improve the quality of care in labour room and maternity operation theatres in public health facilities.</p>\n<p>Objectives:</p>\n<ul>\n<li>To reduce maternal and newborn mortality and morbidity due to preventable causes.</li>\n<li>To improve quality of care during the delivery and immediate post-partum care, timely referrals and enable an effective two-way follow-up system.</li>\n<li>To provide the Respectful Maternity Care to all the pregnant women attending the public health facilities.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9661",
      "difficulty": "easy"
    },
    {
      "text": "The scheme intended for safeguarding the health of elderly population is:",
      "choices": [
        {
          "id": 1,
          "text": "Vayoshri yojana"
        },
        {
          "id": 2,
          "text": "Indradhanush"
        },
        {
          "id": 3,
          "text": "Kayakalp"
        },
        {
          "id": 4,
          "text": "Swasthya suraksha yojana"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The scheme intended for safeguarding the health of elderly population is <strong>Vayoshri yojana.</strong></p>\n<p>Objective: To provide <strong>physical aids and assisted-living devices</strong> for senior citizens belonging to BPL category which can restore near normalcy in their bodily functions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9663",
      "difficulty": "easy"
    },
    {
      "text": "According to the latest guidelines, the recommended treatment regimen for rifampicin-susceptible and isoniazid-resistant tuberculosis is:",
      "choices": [
        {
          "id": 1,
          "text": "Cycloserine, Levofloxacin, Pyrazinamide, Kanamycin for 9 months"
        },
        {
          "id": 2,
          "text": "Rifampicin, Ethambutol, Pyrazinamide, Levofloxacin for 6 months"
        },
        {
          "id": 3,
          "text": "Clofazamine, High dose isoniazid, Ethambutol, Moxifloxacin for 8 months"
        },
        {
          "id": 4,
          "text": "Ethionamide, Pyrazinamide, Moxifloxacin, Kanamycin for 12 months"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>According to the latest guidelines, the recommended treatment regimen for isoniazid mono/poly resistant tuberculosis is <strong>Rifampicin, Ethambutol, Pyrazinamide, Levofloxacin for 6 months.</strong></p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9664",
      "difficulty": "medium"
    },
    {
      "text": "According to the latest RNTCP guidelines, the baseline investigation to rule out Rifampicin resistance is:",
      "choices": [
        {
          "id": 1,
          "text": "BACTEC 460"
        },
        {
          "id": 2,
          "text": "MGIT 960"
        },
        {
          "id": 3,
          "text": "Myco DOT"
        },
        {
          "id": 4,
          "text": "CBNAAT"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>According to the latest RNTCP guidelines, the baseline investigation to rule out Rifampicin resistance is <strong>CBNAAT.</strong></p><hr><h3>Related Pearl: Diagnostic algorithm for Pulmonary TB – National Tuberculosis Elimination Programme (NTEP) 2020 Guidelines</h3><p>Any case of&nbsp;<strong>presumptive pulmonary TB</strong>&nbsp;should undergo <strong>sputum examination + chest X-ray + CB-NAAT</strong></p>\n<ul>\n<li>If sputum and chest X-ray normal:<strong> rule out TB and refer</strong></li>\n<li>If sputum is positive and CB NAAT is positive:<strong>&nbsp;microbiologically confirmed case of TB</strong></li>\n</ul>\n<p>The following protocol is used for <strong>CB-NAAT testing:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e8d17e5087654b588b4b519b350acb71x1280x2558.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9665",
      "difficulty": "easy"
    },
    {
      "text": "The recommended treatment regimen for Paucibacillary leprosy in adults is:",
      "choices": [
        {
          "id": 1,
          "text": "Rifampicin 600 mg monthly + Clofazamine 300 mg monthly, 50 mg daily + Dapsone 100 mg daily for 6 months"
        },
        {
          "id": 2,
          "text": "Rifampicin 600 mg monthly + Dapsone 100 mg daily for 6 months"
        },
        {
          "id": 3,
          "text": "Rifampicin 600 mg monthly + Clofazamine 100 mg monthly, 50 mg daily + Dapsone 50 mg daily for 6 months"
        },
        {
          "id": 4,
          "text": "Rifampicin 600 mg monthly + Dapsone 50 mg daily for 6 months"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The recommended treatment regimen for Paucibacillary leprosy in adults is <strong>Rifampicin 600 mg monthly + Clofazamine 300 mg monthly, 50 mg daily + Dapsone 100 mg daily for 6 months </strong>according to latest guidelies.</p><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9666",
      "difficulty": "medium"
    },
    {
      "text": "According to the Globocon 2018, the most common cancer among males in India is:",
      "choices": [
        {
          "id": 1,
          "text": "Lung"
        },
        {
          "id": 2,
          "text": "Colorectal"
        },
        {
          "id": 3,
          "text": "Liver"
        },
        {
          "id": 4,
          "text": "Lip and oral cavity"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>According to the Globocon 2018, the most common cancer among males in India is <strong>Lip and oral cavity cancer.</strong></p>\n<p>Most common cancers in India:</p>\n<p>Male - Lip and oral cavity</p>\n<p>Female - Breast</p>\n<p>Both sexes - Breast</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9667",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drug is recently approved by FDA to treat adult patients with metastatic urothelial carcinoma that has progressed following prior platinum-based chemotherapy?",
      "choices": [
        {
          "id": 1,
          "text": "Erdafitinib"
        },
        {
          "id": 2,
          "text": "Brolucizumab"
        },
        {
          "id": 3,
          "text": "Pretomanid"
        },
        {
          "id": 4,
          "text": "Pembrolizumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Erdafitinib</strong> has been recently approved by the FDA for the treatment of metastatic urothelial carcinoma in adults that has progressed following prior platinum-based chemotherapy.</p>\n<p>Erdafitinib is a <strong>fibroblast growth factor receptor inhibitor.</strong> FGFR inhibition results in decreased FGFR-related signalling and decreased cell viability in cell lines expressing FGFR genetic alterations.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9668",
      "difficulty": "hard"
    },
    {
      "text": "The maximum approved daily dose of Istradefylline is:",
      "choices": [
        {
          "id": 1,
          "text": "20 mg"
        },
        {
          "id": 2,
          "text": "60 mg"
        },
        {
          "id": 3,
          "text": "40 mg"
        },
        {
          "id": 4,
          "text": "100 mg"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The maximum approved daily dose of Istradefylline is <strong>40 mg.</strong></p>\n<p>Istradefylline has been recently approved by FDA as an <strong>add-on treatment to levodopa in adults with Parkinson’s disease experiencing off episodes.</strong></p>\n<p>It is an adenosine A2A receptor antagonist.</p>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9669",
      "difficulty": "medium"
    },
    {
      "text": "Where will you discard the urine bag?",
      "choices": [
        {
          "id": 1,
          "text": "Yellow bin"
        },
        {
          "id": 2,
          "text": "Red bin"
        },
        {
          "id": 3,
          "text": "Blue bin"
        },
        {
          "id": 4,
          "text": "White bin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Urine bags</strong> are discarded in the <strong>red</strong> bin.</p><hr><h3>Related Pearl: Biomedical waste disposal</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong>&nbsp;<span> Yellow bag </span></strong><strong><span>(non-chlorinated)</span></strong><strong><span>&nbsp;</span>&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Type of Waste</p>\n</td>\n<td>&nbsp;Treatment and Disposal Options</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human anatomical waste</strong></p>\n<p><strong>Animal anatomical waste</strong></p>\n</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n</td>\n</tr>\n<tr>\n<td><strong>Soiled Waste: </strong>Items like dressings, cotton swabs, and plaster casts contaminated with blood and body fluids and bags containing residual discarded blood.</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n<p>or</p>\n<p>Autoclaving/Microwaving/ Hydroclaving</p>\n<p>Later - Shredding/mutilation</p>\n</td>\n</tr>\n<tr>\n<td>Discarded linen, mattresses, beddings contaminated with blood or body fluid,<strong> routine masks, and gowns</strong></td>\n<td>\n<p>Non- chlorinated chemical disinfection<br />followed by incineration or Plazma<br />Pyrolysis or for energy recovery.<br />In absence of the above facilities, shredding,&nbsp;mutilation, or a combination of&nbsp;sterilization and shredding is used.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Microbiology, biotechnology, clinical laboratory waste</strong></p>\n<p>(Autoclave safe plastic bags used)</p>\n<p><strong>Blood bags</strong>, laboratory<br />cultures, stocks or&nbsp;specimens of microorganisms,<br />live or&nbsp;attenuated vaccines,&nbsp;human and animal cell&nbsp;cultures used in&nbsp;research, industrial&nbsp;laboratories, production&nbsp;of biological, residual&nbsp;toxins, dishes, and&nbsp;devices used for&nbsp;cultures.</p>\n</td>\n<td>\n<p>Pre-treatment with nonchlorinated chemicals</p>\n<p>Later - Incineration</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Expired/discarded medicine, cytotoxic drugs</p>\n</td>\n<td>Incineration/plasma pyrolysis/ disposal in a secured landfill</td>\n</tr>\n<tr>\n<td>&nbsp;\n<p><strong>Chemical waste</strong></p>\n<p>Chemicals used in biological production&nbsp;and used or discarded<br />disinfectants.</p>\n</td>\n<td>\n<p>Disposal- incineration/plasma<br />pyrolysis</p>\n<p>Encapsulation-&nbsp;hazardous waste treatment, storage, and&nbsp;disposal facility.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Chemical liquid</strong>&nbsp;<strong>waste</strong> :<br />Liquid waste generated&nbsp;due to the use of chemicals&nbsp;in the production of<br />biological and used or&nbsp;<strong>discarded disinfectants,</strong>&nbsp;silver X-ray film<br />developing liquid,<br />discarded formalin,<br />infected <strong>secretions,</strong><br /><strong>aspirated body&nbsp;fluids</strong>,&nbsp;liquid from&nbsp;laboratories and floor&nbsp;washings, cleaning,&nbsp;house-keeping and<br />disinfecting activities&nbsp;etc.</p>\n<p>&nbsp;</p>\n</td>\n<td>After resource recovery, the chemical<br />liquid waste shall be pre-treated before&nbsp;mixing with other wastewater.&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong>&nbsp; Red&nbsp;bag (non-chlorinated)&nbsp;&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td><strong>&nbsp;Type of Waste</strong></td>\n<td>\n<p><strong>&nbsp;<span>Treatment and Disposal Options</span></strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Recyclable contaminated</strong> waste</p>\n<p>Contaminated waste tubing, bottles, intravenous tubes and sets, <strong>catheters,</strong> <strong>urine bags</strong>, syringes (without needles and fixed needle syringes with their needles cut), <strong>vacutainers with</strong> <strong>needles cut,</strong> and gloves.</p>\n</td>\n<td>\n<p><strong>Autoclaving/Microwaving/<br />Hydroclaving</strong></p>\n<p>Followed by Shredding/mutilation</p>\n<p>And later, Energy recovery/Plastics to diesel or fuel oil/road-making</p>\n<p>Not to be sent to landfill</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><strong>&nbsp; White (translucent)&nbsp;&nbsp;<br />(puncture-proof, leak-proof containers)</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Type of Waste</strong></td>\n<td>\n<p><strong>Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Waste Sharps including metals.</strong></p>\n<p>Needles, syringes with fixed needles, needles from needle tip cutter or burner, scalpels, blades, or any other <strong>contaminated sharp</strong> object that may cause puncture and cuts. This includes both used, discarded, and contaminated metal sharps</p>\n</td>\n<td>\n<p>Autoclaving/ Dry heat sterilization</p>\n<p>Followed by - <strong>Shredding/mutilation</strong>/<br />encapsulation</p>\n<p>Later by - Iron foundries/sanitary landfill/waste sharps</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p>&nbsp;<span><strong><span>&nbsp; Blue&nbsp;&nbsp;</span><br /></strong></span><span><strong><span>(Puncture proof and leak proof containers with blue colored marking)</span></strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type of Waste&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Glassware</strong></p>\n<p>Broken or discarded and contaminated glass including medicine <strong>vials</strong> and <strong>ampules except</strong> those containing <strong>cytotoxic</strong> waste.</p>\n<p><strong>Metallic body implants</strong></p>\n</td>\n<td>\n<p>Sodium hypochlorite/Autoclaving/<br />Microwaving/Hydroclaving</p>\n<p>Later - Recycling</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;Note: <strong>Ash</strong> from the <strong>incineration</strong> of biomedical waste shall be disposed of at a <strong>common hazardous waste treatment and disposal facility</strong>. However, it may also be disposed of in a <strong>municipal landfill</strong>, <strong>if</strong> the toxic metals in incineration ash are <strong>within</strong> the <strong>regulatory quantities</strong> as defined under the Hazardous Waste (Management and Handling and Transboundary Movement) Rules, 2008 as amended from time to time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9670",
      "difficulty": "medium"
    },
    {
      "text": "Under Rashtriya Bal Swasthya Karyakram, children are screened for :",
      "choices": [
        {
          "id": 1,
          "text": "Convulsive disorders"
        },
        {
          "id": 2,
          "text": "Vitamin A deficiency"
        },
        {
          "id": 3,
          "text": "Attention deficit hyperactivity disorder"
        },
        {
          "id": 4,
          "text": "All of the above"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Under Rashtriya Bal Swasthya Karyakram, <strong>children are screened for all of the mentioned conditions.</strong></p>\n<p>Selected health conditions for child (0-18 years) health screening and early intervention services are:</p>\n<p>Defects:</p>\n<ul>\n<li>Neural tube defect</li>\n<li>Down&rsquo;s syndrome</li>\n<li>Cleft lip and palate</li>\n<li>Talipes</li>\n<li>Developmental dysplasia of hip</li>\n<li>Congenital cataract, congenital deafness, congenital heart disease</li>\n<li>Retinopathy of prematurity</li>\n</ul>\n<p>Deficiencies:</p>\n<ul>\n<li>Anemia especially severe anemia</li>\n<li>Vitamin A deficiency</li>\n<li>Vitamin D deficiency</li>\n<li>Severe acute malnutrition</li>\n<li>Goitre</li>\n</ul>\n<p>Diseases:</p>\n<ul>\n<li>Scabies, fungal infections and eczema</li>\n<li>Otitis media</li>\n<li>Rheumatic heart disease</li>\n<li>Reactive airway disease</li>\n<li>Dental caries</li>\n<li>Convulsive disorders</li>\n</ul>\n<p>Developmental delays and disabilities:</p>\n<ul>\n<li>Vision, hearing and neuro-motor impairment</li>\n<li>Motor, cognitive and language delay</li>\n<li>Autism</li>\n<li>Learning disorder</li>\n<li>Attention deficit hyperactivity disorder</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9671",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man, who has history of contact with a known case of influenza, is having fever, cough, and runny nose since today morning. Rapid antigen test turns out to be positive. The endonuclease inhibitor that can be used for his treatment is ___________.",
      "choices": [
        {
          "id": 1,
          "text": "Oseltamivir"
        },
        {
          "id": 2,
          "text": "Baloxavir"
        },
        {
          "id": 3,
          "text": "Zanamivir"
        },
        {
          "id": 4,
          "text": "Favipravir"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>endonuclease</strong> <strong>inhibitor</strong> which can be used for the treatment of acute uncomplicated influenza in adults is <strong>baloxavir marboxil.</strong></p>\n<p>It is a novel drug that was approved by the FDA in 2018. It is used to treat acute&nbsp;<strong>uncomplicated influenza</strong> in patients <strong>12 years </strong>of age<strong> and older</strong> who have been symptomatic for <strong>less than 48 hours. </strong></p>\n<p>It is a <strong>selective inhibitor </strong>of influenza cap-dependent<strong> endonuclease</strong> which blocks proliferation by inhibiting mRNA synthesis.</p><p><strong>Recent Update</strong>: In 2020, the FDA expanded the approved indication for baloxavir marboxil (Xofluza) to include <strong>post-exposure prevention of influenza</strong> (flu) for patients 12 years of age and older after contact with an individual who has the flu.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9672",
      "difficulty": "medium"
    },
    {
      "text": "The topical retinoid that selectively targets retinoic acid receptor gamma is:",
      "choices": [
        {
          "id": 1,
          "text": "Adapalene"
        },
        {
          "id": 2,
          "text": "Tazarotene"
        },
        {
          "id": 3,
          "text": "Tretinoin"
        },
        {
          "id": 4,
          "text": "Trifarotene"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The topical retinoid that selectively targets retinoic acid receptor gamma is <strong>Trifarotene.</strong></p>\n<p>It has been recently approved by the FDA for the <strong>topical treatment of acne vulgaris in patients aged 9 years or older.</strong></p>\n<p>Adapalene, Tazarotene and Tretinoin target both RAR-beta and RAR-gamma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9673",
      "difficulty": "hard"
    }
  ]
}